相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Parakkal Deepak et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G. Feagan et al.
LANCET (2021)
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Bruce E. Sands et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Modulation of sphingosine-1-phosphate in ulcerative colitis
Marjorie Argollo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Vince B. C. Biemans et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience
Sailish Honap et al.
JOURNAL OF CROHNS & COLITIS (2020)
Paradoxical gastrointestinal effects of interleukin-17 blockers
Marine Fauny et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Brian G. Feagan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
JAK inhibitors and infections risk: focus on herpes zoster
Flavia Sunzini et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof-of-concept study
G. D'Haens et al.
JOURNAL OF CROHNS & COLITIS (2019)
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
Tamara Perez-Jeldres et al.
FRONTIERS IN PHARMACOLOGY (2019)
Intestinal fibrosis
Marco Vincenzo Lenti et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
Yoram Bouhnik et al.
GUT (2018)
Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2018)
Epithelial-mesenchymal transition in Crohn's disease
H. Jiang et al.
MUCOSAL IMMUNOLOGY (2018)
Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease
Amy Hemperly et al.
INFLAMMATORY BOWEL DISEASES (2018)
Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn's Disease Strictures Ex Vivo
Marta Truffi et al.
INFLAMMATORY BOWEL DISEASES (2018)
Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming
Olga A. Sukocheva
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication
Pardis Pakshir et al.
MATRIX BIOLOGY (2018)
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
Sudarshan Paramsothy et al.
MUCOSAL IMMUNOLOGY (2018)
Epithelial down-regulation of the miR-200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition
Shameer J. Mehta et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease (Review)
Ray K. Boyapati et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease
T. Karuppuchamy et al.
MUCOSAL IMMUNOLOGY (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis
Jacopo Di Gregorio et al.
PLOS ONE (2017)
Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up
William J. Sandborn et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience
Mariangela Allocca et al.
DIGESTIVE AND LIVER DISEASE (2017)
Modulation of sphingosine-1-phosphate in inflammatory bowel disease
Laurent Peyrin-Biroulet et al.
AUTOIMMUNITY REVIEWS (2017)
Unmet Therapeutic Needs: Focus on Intestinal Fibrosis Surgical Approach: Resection, Strictureplasty and Others
Diane Mege et al.
DIGESTIVE DISEASES (2017)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease
Florian Rieder et al.
JOURNAL OF CROHNS & COLITIS (2016)
Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease
Paolo Giuffrida et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2016)
Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2015)
Small molecule drugs with immunomodulatory effects in cancer
Adrian G. Murphy et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 2 and Selectively Couples to Gα12/13/Rho/ROCK to Induce Myofibroblast Contraction
Katrin Sobel et al.
MOLECULAR PHARMACOLOGY (2015)
In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts
Anke Nijhuis et al.
CLINICAL SCIENCE (2014)
The role of transforming growth factor (TGF)-β in modulating the immune response and fibrogenesis in the gut
Paolo Biancheri et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD
Giovanni Latella et al.
JOURNAL OF CROHNS & COLITIS (2014)
An update on the biology of sphingosine 1-phosphate receptors
Victoria A. Blaho et al.
JOURNAL OF LIPID RESEARCH (2014)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Sphingosine 1-Phosphate (S1P) Receptor Agonists Mediate Pro-fibrotic Responses in Normal Human Lung Fibroblasts via S1P2 and S1P3 Receptors and Smad-independent Signaling
Katrin Sobel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis
Paolo Biancheri et al.
FIBROGENESIS & TISSUE REPAIR (2013)
Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats
Dov Wengrower et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
N-Cadherin Is Overexpressed in Crohn's Stricture Fibroblasts and Promotes Intestinal Fibroblast Migration
John P. Burke et al.
INFLAMMATORY BOWEL DISEASES (2011)
Fibroblast Activation Protein Expression in Crohn's Disease Strictures
Laura Rovedatti et al.
INFLAMMATORY BOWEL DISEASES (2011)
Development of the Crohn's Disease Digestive Damage Score, the Lemann Score
Benjamin Pariente et al.
INFLAMMATORY BOWEL DISEASES (2011)
Balancing acts: the role of TGF-β in the mucosal immune system
Joanne E. Konkel et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
T-cell-directed therapies in inflammatory bowel diseases
Giovanni Monteleone et al.
CLINICAL SCIENCE (2010)
Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease
Lynn W. Maines et al.
INFLAMMOPHARMACOLOGY (2010)
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis
Ashley J. Snider et al.
FASEB JOURNAL (2009)
VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis
Franco Scaldaferri et al.
GASTROENTEROLOGY (2009)
Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures
A. Di Sabatino et al.
GUT (2009)
Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development
Rui-Dong Duan et al.
PROGRESS IN LIPID RESEARCH (2009)
Blockade of transforming growth factor β upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa
A. Di Sabatino et al.
GUT (2008)
Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives
Florian Rieder et al.
JOURNAL OF CROHNS & COLITIS (2008)
Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α
K Aertgeerts et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts
BC McKaig et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2002)
Stricture formation in Crohn's disease - The role of intestinal fibroblasts
MC Regan et al.
ANNALS OF SURGERY (2000)
分享论文
